All In MedTech

Device Trial Radar · NCT04879940

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients With Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Feb 23, 2022

Primary completion

Jun 16, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 10, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II prospective clinical trial in which patients with prostate carcinoma and obstructive lower urinary tract symptoms electing for radiation therapy will undergo Prostatic Artery Embolization (PAE) prior to treatment. PAE will be administered by Interventional Radiology. Patients will be seen for follow-up at 6 weeks and 12 weeks following PAE after which they will start definitive radiotherapy. After completion of radiotherapy the patient will be seen at 12 weeks

Conditions

  • Prostate Carcinoma
  • Benign Prostatic Hyperplasia

Interventions

  • Merit Medical EmbospheresDevice

    Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.

  • Radiation TherapyRadiation

    Patients will undergo standard of care definitive radiation therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Prostate Symptom ScoreTime frame: At screening, Day of PAE, and 6 weeks & 12 weeks after PAE

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.